24 results about "Oral route" patented technology

The application provides a copper selenide-halloysite-mannose composite drug delivery system, which comprises a carrier, the carrier is halloysite nanotubes (HNTs), copper selenide nanoparticles (CuSe) are in situ grown on the tube wall of the halloysite nanotubes to form a composite CuSe@HNTs; and mannose is loaded in the lumen of the CuSe@HNTs to form a composite drug delivery system CuSe@HNTs@ME. The application also provides a preparation method and application of the copper selenide-halloysite-mannose composite drug delivery system. The drug delivery system can maintain stability in a gastric acid environment, directly reaches an intestinal inflammation site through an oral route, and significantly reduces intestinal inflammation symptoms.

The invention relates to the technical field of biology, in particular to recombinant lactic acid bacteria capable of improving the serum melatonin level and a construction method of the recombinant lactic acid bacteria. According to the recombinant lactic acid bacteria, melatonin synthetase AANAT and HIOMT genes are introduced through a genetic engineering technology and are stably expressed in genomes of the recombinant lactic acid bacteria, so that the recombinant lactic acid bacteria have the capability of secreting melatonin synthetase. The lactic acid bacteria are food-grade strains without resistance selection markers, have good biological safety and can enter intestinal tracts through oral administration. After oral administration, the recombinant lactic acid bacteria secrete melatonin synthetase in intestinal tracts, promote intestinal cells to synthesize melatonin, and improve the level of melatonin in serum through an intestinal-blood barrier. Serum detection shows that the recombinant lactic acid bacteria can significantly improve the concentration of serum melatonin. Compared with the prior art, the invention provides a safe and effective food-grade recombinant lactic acid bacteria preparation which is suitable for promoting the improvement of the endogenous melatonin level of a human body and has a wide application prospect.

The subject of the invention is a new system in the form of an instant self-emulsifying powder, their preparation process as well as the application of this oily system associated with one or a mixture of cyclodextrins for the instant formation of a solid spherical system of effervescent or non-self-emulsifying granule or pellet types (Spontaneous Powder Self Emulsifying Drug Delivery Systems (SP-SEDDS®)). And for the encapsulation of a substance of therapeutic interest. Applications to the encapsulation of one or more substances of interest, in particular therapeutic or preventive, nutritional, and usable in pharmacy, veterinary, nutrition or agri-food by oral route.

The application discloses a novel coronavirus vaccine based on controllable secretion expression of attenuated salmonella, a preparation method and application thereof, and is used for preventing the novel coronavirus. The application constructs controllable, stable and secretory expression plasmids of different antigen domain proteins of the novel coronavirus and attenuated salmonella expression strains of the different antigen domain proteins; a plurality of attenuated salmonella antigen presentation strains which can controllably and secretively express in antigen presenting cells are mixed, and through an oral route, the plurality of different antigen proteins can be efficiently secretively expressed in the antigen presenting cells by means of the unique secretion system of the attenuated salmonella after administration. The secretively expressed antigenic proteins can be effectively processed and presented by the antigen presenting cells, and finally the immune system is activated / regulated, higher titer antibodies are generated, and the vaccine plays a role.

The present invention in particular relates to a method for reducing virus shedding, colonization of lymphoid tissue, and / or lymphoid depletion caused by or associated with a porcine circovirus type 2 (PCV2) infection in a pig, the method comprising administering orally to the pig an immunogenic composition comprising non-replicating PCV2 antigen. In one example, an immunogenic composition is administered via the oral route to a pig, wherein the immunogenic composition comprises a recombinantly produced and purified PCV2 ORF2 protein. This allows to simply reduce virus shedding, colonization of lymphoid tissue, and / or lymphoid depletion caused by associated with a PCV2 infection in the pigs, while simultaneously reducing the propensity for adverse reactions, eliminating the risk of injection site reactions, avoiding pain, and putting less stress on the animals.

The invention relates to a pharmaceutical composition in the form of a spheroid dosage form that can be absorbed by oral route, said spheroid containing, as the sole active ingredient with antimalarial activity, a therapeutically effective amount of at least 200 mg of artesunate, for use as a drug.

Immunogenic formulations by oral route comprising: i) one or more chimeric proteins consisting of an immunologically associated antigen from a pathogenic microorganism of the pig and a molecular adjuvant CD154 from the pig; ii) an adjuvant selected from the cyclic dinucleotide monophosphate family; and iii) an excipient acceptable for oral immunization. A method of inducing an immune response against a pathogen characterized in that an immunogenic formulation comprising: i) one or more chimeric proteins formed from an immunologically related antigen from a swine pathogen fused with a molecular adjuvant CD154 from the swine is administered to the swine by oral route; and ii) an adjuvant selected from the cyclic dinucleotide monophosphate family.

Compounds comprising at least one GPCR agonist and / or antagonist and at least one oral bioavailability enhancing moiety and / or protein binding enhancing moiety, for treatment of GPCR agonist or antagonist responsive diseases and conditions via the oral route of administration, among other routes.

The present invention relates to a method of inducing an immune response in a subject comprising orally administering to the subject an immunogenic composition comprising a non-replicating viral antigen. In one example, an immunogenic composition is administered to a pig by an oral route, where the immunogenic composition comprises a recombinant viral capsid protein capable of forming a virus-like particle. This allows for simple induction of immune responses in pigs while reducing the propensity of adverse reactions, eliminating the risk of reactions at the injection site, avoiding pain, and reducing stress in animals.

The present invention provides a synergistic composition comprising Boswellia- derived Frankincense oil and boswellic acid as well as methods for the synthesis of the same. Said synergistic composition comprising Frankincense oil and boswellic acid is prepared by subjecting Boswellia serrata resin gum to hydro-steam distillation process at a slightly elevated pressure, and for a short period of time, without using any organic solvents for extraction. Said synergistic composition is also prepared by combining Boswellic extract comprising at least 5 % by weight of Boswellic acid with Frankincense oil, with the combined product remaining as a clear oil, and offering the benefits of both Boswellic extract containing boswellic acid, and Frankincense oil. Said synergistic composition comprising Frankincense oil and boswellic acid is administered through topical, transdermal or oral route for the treatment of skin cancer, breast cancer, arthritis, and IBS.

There is disclosed a method for treating post-traumatic stress disorder (PTSD) or treating anxiety comprising administering flumazenil. The flumazenil may be administered non-orally and / or at least daily. The non-oral route of administration may be subcutaneous, buccal, sublingual, nasal, transdermal, intravenous, intramuscular injection, or rectal. The present disclosure further provides a flumazenil dosage form comprising (a) a buccal flumazenil lozenge formulation; (b) a flumazenil dissolving sublingual strip formulation; (c) a subcutaneous injection dosage form of an aqueous solution of flumazenil; or (d) a rectal suppository formulation, wherein each flumazenil dosage form is capable of systemically delivering from about 0.1 mg to about 3 mg of flumazenil. There is further disclosed a chronic (at least one week or longer) treatment regimen of flumazenil to reach the brain of a patient having anxiety or PTSD, comprising administering a daily non-oral dose of flumazenil.

The invention discloses an intestinal responsive mucus adhesion-permeation conversion type oral delivery system as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out self-crosslinking on succinylated soy isolate protein and hydroxyethylated chitosan, and then adding pterostilbene to carry out a co-precipitation reaction, so as to prepare pterostilbene-loaded mucus permeable nanoparticles; and carrying out surface modification on the pterostilbene-loaded mucus permeable nano-particles by adopting high methoxyl pectin, so as to prepare the intestinal tract responsive mucus adhesion-permeation conversion type oral delivery system. According to the oral delivery system provided by the invention, ingenious combination and intelligent conversion of gastric environment resistance, intestinal responsive release, intestinal mucus adhesion and permeability are realized, and the loading rate of pterostilbene, gastrointestinal tract resistance and mucus permeability are effectively improved; therefore, the intestinal epithelial cell uptake efficiency and intracellular antioxidant and anti-inflammatory activity of the free pterostilbene through oral administration are improved, and the preparation method has a good application prospect in the field of oral delivery of bioactive substances.

The utility model relates to a kind of energy-saving pollution-free discharge toilet, involve sanitary ware technical field, solve the insufficient of current toilet water, no disinfecting function, easy to cause fecal-oral route disease transmission, the technical scheme for using is that: toilet seat part is equipped with toilet bowl, seat ring of toilet cover is equipped with seat cover, and toilet bowl is equipped with steam jet head;Dry and wet separation device's feed end is connected with the discharge opening of toilet bowl, and outlet end is connected with sewer through first steam disinfecting device through drain bend, and outlet end is connected with black water tank by second steam disinfecting device, and the outlet end of black water tank is connected between first steam disinfecting device and drain bend;Toilet box part is equipped with steam generating device and water supply device, and control module controls the work of the aforementioned each part.The excrement of the utility model is separated after solid-liquid separation and carried out high-temperature steam disinfecting, avoid the spread of fecal-oral route disease;Black water tank collects liquid component to flush drain bend, and water consumption is low;Steam jet head disinfects and cleans toilet bowl, clean and sanitary.

The invention discloses a lybologarithm nasal spray and a preparation method thereof. The lybologarithm nasal spray comprises lybologarithm, an osmotic pressure regulator, a pH regulator, a bacteriostatic agent, a surfactant, a suspending aid and a solvent. According to the preparation method provided by the invention, the raw material medicines and part of the surfactant are mixed and then are subjected to co-micro-grinding, the sedimentation ratio of the obtained nasal spray is not lower than 0.9, the uniformity of the delivered dose is good, and the bioavailability is obviously superior to that of the prior art. Compared with an oral administration way, the novel dosage form composition provided by the invention has the advantages that the in-vivo bioavailability of the active ingredients of the medicine can be remarkably improved, the influence of food on medicine absorption is avoided through nasal administration, and the urgent demand of relieving symptoms as soon as possible can be met; meanwhile, administration dosage is reduced, and side effects are reduced.

The invention provides a pharmaceutical composition containing metformin and glibenclamide. The pharmaceutical composition is used for treating Parkinson's disease. The invention also comprises the combined application of metformin and glibenclamide. In a preferred embodiment, the pharmaceutical composition is administered by an oral route.

The present invention describes a composition comprising beta-caryophyllene, docosahexaenoic acid and eugenol for use as analgesic and anti-inflammatory antioxidants for the central and peripheral nervous system, administered by oral route, the compounds are useful as analgesics for chronic pain disorders, chronic inflammatory pain, chronic neuralgia and as anti-inflammatory antioxidants for the central and peripheral nervous systems.

The present invention relates to a composition of a long-acting bioadhesive endoparasiticide gel based on an isoxazoline alone or in combination with other antiparasitic agents, having a high degree of adhesion to oral mucosa and high palatability greatly facilitating the dosing thereof, and to methods for preparing the same. Ectoparasitosis is a parasitic disease caused by fleas, ticks and mites that infest the surface layers of the skin in small animals. Control of this illness is of great importance and advantageously achievable through the use of appropriate antiparasitic agents such as isoxazolines, being a chemical compound widely administered by oral route in tablet form due to the organoleptic and physicochemical characteristics of the compositions known up to the present. The present invention demonstrates that it is possible to administer isoxazolines in the pharmaceutical form of an oral gel at concentrations of up to 20.0% weight / volume, overcoming the organoleptic and physicochemical restrictions of the compositions known up to the present. Factors never heretofore included in oral endoparasiticide compositions based on isoxazolines, presenting a wide differential advantage compared with the compositions known up to the present.

The present application provides a kind of lactobacillus gasseri LN32 and lactobacillus crispatus LN70 containing probiotic composition and application in reducing the risk of vaginal infection, belong to microbial application technical field.Containing 4 strains of probiotics, including lactobacillus plantarum LN66, lactobacillus rhamnosus LN56, lactobacillus gasseri LN32 and lactobacillus crispatus LN70.The probiotic composition is realized by oral route, vaginal flora reconstruction, inhibit the reproduction of gardnerella vaginalis and candida albicans, increase lactobacillus colonization, eliminate abnormal leucorrhea, vaginal burning and itching, frequent urination, urgency and pain.The probiotic composition is combined with conventional carrier, applied to prepare food, dietary supplement or drug for preventing and / or treating vaginal and urethral microecological disorder, bacterial vaginitis, mycotic vaginitis and urethral infection, and then the present application realizes inhibiting harmful bacteria in vagina, reconstructing vaginal flora to reduce the risk of vaginal infection and reduce the risk of urethral infection.

The invention relates to novel medical application of high-purity natural borneol, in particular to application of the high-purity natural borneol in preparation of drugs for relieving heart failure and improving myocardial injury. According to the high-purity natural borneol disclosed by the invention, the expression levels of TGF-beta and Smad3 are reduced and the expression level of Smad7 is increased by adjusting a TGF-beta / Smad signal channel, so that the left ventricular ejection fraction of heart failure is improved, the myocardial fibrosis proportion is reduced and the myocardial cell apoptosis rate is reduced. The pharmaceutical composition takes high-purity natural borneol as a main component and can be administered in a subcutaneous injection or oral administration way, the dosage range of the pharmaceutical composition is 0.2 g / kg to 0.8 g / kg, and the pharmaceutical composition can be prepared into tablets, capsules and injections. According to the invention, the heart function is obviously improved, the level of serum myocardial injury markers is reduced, the biocompatibility and the safety are good, an efficient and safe new scheme is provided for the treatment of heart failure, and a theoretical basis and a practical support are provided for the development of natural medicines.

The invention belongs to the field of biological medicine, and particularly provides novel application of an imidazole pyridine derivative, and the chemical formula of the imidazole pyridine derivative is 4-{5 '-[3'-propyl-2 '-[3' '-(1' '-methyl) indolyl]-imidazole [4, 5-b] pyridine] group} morpholine. The invention provides an application of the imidazole pyridine derivative or the pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. When the compound disclosed by the invention is used for treating the pulmonary fibrosis, after animals with the pulmonary fibrosis are subjected to oral administration and inhalation administration, the lung function, the lung index, the lung tissue lesion and the fibrosis degree of model animals in different administration groups are obviously improved, so that an appropriate dosage of X22 has a treatment effect on the animals with the pulmonary fibrosis; and the pulmonary fibrosis improvement effect of the X22 inhalation way is obviously better than that of the X22 oral administration way and the existing conventional medicine.

Formulations comprising complexes of peptides with hydrophobic bioactive molecules are described herein. The invention more specifically relates to collagen peptide and curcuminoid complexes and compositions comprising the complexes. The compositions and formulations comprising the protein hydrolysate peptide-hydrophobic bioactive molecule complexes are water-soluble, stable at physiological and acidic pH, synergistically enhance the systemic bioavailability of the biomolecules and peptides, and are capable of delivering a high therapeutically effective amount of the bioactive molecules via oral route. The compositions and formulations comprising the collagen peptide-curcuminoid complexes provide significantly high levels of bioavailable curcuminoids that are water soluble and stable at physiological and acidic pH along with significant anti-inflammatory effects offered by collagen peptides. The invention further provides a process for preparing the peptide-bioactive molecule complexes, compositions and oral formulations comprising the collagen peptide-curcuminoid complex.

The application provides application of N-acetyl-L-glutamic acid in preparation of a medicine for preventing and treating type 1 diabetes of children, and belongs to the technical field of biological medicine and microecological preparation. The N-acetyl-L-glutamic acid provided by the application can be administered through an oral route, and has a clear effect of protecting islet function, reducing blood sugar, delaying or reducing the incidence of diabetes in the prevention and adjuvant treatment of type 1 diabetes of children.

Methods and apparatus for use in continuous manufacturing (CM) of engineered particulate formulations, including formulations containing therapeutic protein or mAbs, are provided. The resulting products have wide ranges of application, and may be formulated for pulmonary drug delivery systems. Pulmonary drug delivery systems produced according to the CM systems / methods may be used instead of conventional IV, SQ or oral route of administrations.

A device for applying an integrated therapeutic method for treating tinnitus is disclosed. The method provides the administration of noises, by means of the dedicated technical device, low-frequency and high-frequency electromagnetic waves, by means of the same device, and, if needed, oral functional-adjusting substances. Preferably, the method includes a biochemical step providing the administration of capsules or solutions by oral route and a physical step for administering acoustic signals and electromagnetic waves.